Floatz logo

Durvalumab

Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

ModernaTX, Inc.monoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed/Refractory Solid Tumor Malignancies or Lymphoma cohort.

Asset / SponsorPhaseRating
Mrna-2416
ModernaTX, Inc.
Phase 1/2CCC

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →